BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 9, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 2007

View Archived Issues

Migenix reports preliminary interim results from phase II study of celgosivir for hepatitis C

Read More

New therapeutic option for pruritus reported in recent Janssen patent

Read More

GSK patent claims new pharmaceutically acceptable salts of sildenafil

Read More

Novel agents for treating diabetes disclosed in recent patent literature

Read More

KW-0761 investigated in phase I study in lymphoma patients

Read More

Stem cell transplant plus T-cells with bispecific antibody studied in lymphoma

Read More

ImmuneRegen and DelSite enter agreement to design and develop pandemic flu treatment

Read More

Preclinical studies shed light on the activity of ofatumumab in B-cells

Read More

Possible effect on survival seen with AL-02 in amyotrophic lateral sclerosis

Read More

KNS-760704 doses up to 300 mg safe in healthy volunteers

Read More

Recombinant DNA Advisory Committee reports its assessment of SAE in trial of tgAAC-94

Read More

Alizyme enters partnership and codevelopment agreement with TSD Japan for Colal-Pred

Read More

The Statens Serum Institut initiates phase I clinical trial of TB vaccine HyVac4-IC31

Read More

AVEO and Lilly sign agreement for clinical drug response project

Read More

Inhibiton's ICA-1 compound effective in in vitro testing in various cancer cell lines

Read More

Ipsogen undertakes pilot JAK2 cancer biomarker study with AstraZeneca

Read More

Phase II studies commence for Portola's novel antiplatelet agent, PRT-060128

Read More

Positive results reported for controlled-release rheumatology product, MIST-B04

Read More

Preliminary results of OvaRex ovarian cancer study fail to meet primary endpoint

Read More

SGX submits IND application to FDA for SGX-523

Read More

Newron initiates preclinical development of sodium channel blocker NW-3509

Read More

Myriad Genetics submits IND on Vivecon

Read More

Immtech Pharmaceuticals grants license to BioAlliance for pafuramidine maleate in Europe

Read More

Karo Bio initiates phase I clinical studies of KB-3305 for type 2 diabetes

Read More

FDA approves Medarex's two IND applications for MDX-1342 in CLL and arthritis

Read More

FDA Oncologic Drugs Advisory Committee rejects Genentech's Avastin for breast cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 8, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 8, 2025.
  • Mesothelin is biomarker, potential target in arthritic bone damage

    BioWorld Science
    In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
  • 3D rendering of prion structure

    Epigenetic technology could eliminate misfolded prion proteins

    BioWorld Science
    The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing